Passage Bio, Inc. Gains 23.31%
Mon, Oct 12, 2026 at 07:04 PM
Passage Bio, Inc. (PASG:NASDAQ) jumped higher at $4.55, a gain of 23.3%. On Mon, Oct 12, 2026, PASG:NASDAQ touched a New 2-Week Intraday Low of $3.61. The stock appeared on our News Catalysts scanner on Sat, Sep 26, 2026 at 10:02 PM in the 'MISCELLANEOUS' category. From Mon, Sep 28, 2026, the stock recorded 10.00% Up Days and 36.36% Green Days
About Passage Bio, Inc. (PASG:NASDAQ)
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
Top 10 Gainers:
- Mobile-health Network Solutions (MNDR:NASDAQ), 257.65%
- Linkers Industries Limited (LNKS:NASDAQ), 138.37%
- J-Star Holding Co. Ltd. (YMAT:NASDAQ), 125.58%
- Euro Tech Holdings Company Limited (CLWT:NASDAQ), 58.09%
- Bumble Inc. (BMBL:NASDAQ), 49.61%
- WF Holding Limited (WFF:NASDAQ), 40.6%
- Alaunos Therapeutics, Inc. (TCRT:NASDAQ), 33.62%
- The OLB Group, Inc. (OLB:NASDAQ), 32.16%
- Eastern International Ltd. (ELOG:NASDAQ), 25.45%
- Passage Bio, Inc. (PASG:NASDAQ), 23.31%